FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of
Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced
solid tumors. Qualifying genomic alterations will be identified through molecular assays
as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or
other similarly certified laboratories prior to enrollment into any of the arms. The
study will consist of a screening period, a treatment period, a long-term extension
phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up
assessments.

Inclusion Criteria:

- Low Grade Glioma & Low-Grade Glioma Extension: a relapsed or progressive LGG with
documented known activating BRAF alteration.

- Advanced Solid Tumor: locally advanced or metastatic solid tumor with documented
known or expected to be activating RAF fusion.

- Participants must have histopathologic verification of malignancy at either original
diagnosis or relapse.

- Must have received at least one line of prior systemic therapy and have documented
evidence of radiographic progression.

- Must have at least 1 measurable lesion as defined by RANO (Arms 1 & 2) or RECIST
v1.1 (Arm 3) criteria

Exclusion Criteria:

- Participant's tumor has additional previously-known activating molecular
alterations.

- Participant has symptoms of without radiographically recurrent or radiographically
progressive disease.

- Known or suspected diagnosis of neurofibromatosis type 1 (NF-1) via genetic testing
or current diagnostic criteria.

Other inclusion/exclusion criteria as stipulated by protocol may apply